US
CA
NZ
UK
AU
IND
Last update at 2025-06-13T20:00:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Addex Therapeutics Ltd (ADXN) Q3 2024 Earnings Call Highlights: Strategic Partnerships and ...
Sat 23 Nov 24, 07:01 AMU.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.02%
Tue 27 Aug 24, 09:35 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -20.80421M | -15.35191M | -12.85860M | -14.78060M | -1.64480M |
| Minority interest | - | - | - | - | - |
| Net income | -21.06857M | -15.41493M | -12.92810M | -14.90912M | -1.64480M |
| Selling general administrative | 7.30M | 5.14M | 5.15M | 4.26M | 4.72M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 1.42M | 2.92M | 3.61M | 2.53M | 5.90M |
| Reconciled depreciation | 0.32M | 0.35M | 0.38M | 0.33M | 0.00294M |
| Ebit | -20.52021M | -15.50592M | -12.24327M | -14.83431M | -1.42462M |
| Ebitda | -20.16781M | -15.15298M | -11.82921M | -14.23344M | -1.42169M |
| Depreciation and amortization | 0.35M | 0.35M | 0.41M | 0.60M | 0.00294M |
| Non operating income net other | - | - | - | - | - |
| Operating income | -20.52021M | -15.50592M | -12.24327M | -14.83431M | -1.42463M |
| Other operating expenses | 21.94M | 18.42M | 15.86M | 17.37M | 7.47M |
| Interest expense | 0.05M | 0.06M | 0.07M | 0.13M | 0.22M |
| Tax provision | 0.00000M | 0.00000M | 0.00000M | 0.00000M | 0.00000M |
| Interest income | 0.03M | 0.00532M | 0.04M | 0.18M | 0.22M |
| Net interest income | -0.01965M | -0.05769M | -0.03420M | -0.09164M | -0.22017M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 0.26M | 0.06M | 0.07M | 0.13M | 0.00000M |
| Total revenue | 1.42M | 2.92M | 3.61M | 2.76M | 6.04M |
| Total operating expenses | 21.94M | 18.42M | 15.86M | 17.37M | 7.47M |
| Cost of revenue | - | - | - | 0.23M | 0.14M |
| Total other income expense net | -0.28401M | 0.15M | -0.61533M | 0.05M | -0.22017M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -20.80421M | -15.35191M | -12.85860M | -14.78060M | -1.64480M |
| Net income applicable to common shares | -20.80421M | -15.35191M | -12.85860M | -14.78060M | -1.64480M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 4.64M | 8.28M | 22.54M | 20.18M | 33.03M |
| Intangible assets | - | - | - | - | 25.52M |
| Earning assets | - | - | - | - | - |
| Other current assets | 0.22M | 871.88M | 1.12M | 0.66M | 0.72M |
| Total liab | 3.50M | 3.37M | 5.61M | 5.57M | 7.50M |
| Total stockholder equity | 1.15M | 4.91M | 16.93M | 14.61M | 25.52M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 1.40M | 1.72M | 2.06M | 1.51M | 1.98M |
| Common stock | 1.84M | 1.15M | 49.27M | 32.85M | 32.85M |
| Capital stock | 1.84M | 1.15M | 49.27M | 32.85M | 32.85M |
| Retained earnings | -360.41824M | -349.86201M | -329.05780M | -313.70589M | -300.84729M |
| Other liab | - | - | 1.28M | 1.69M | 1.65M |
| Good will | - | - | - | - | - |
| Other assets | - | 0.05M | 0.06M | 0.06M | 0.07M |
| Cash | 3.87M | 6.96M | 20.48M | 18.70M | 31.54M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 2.89M | 3.28M | 4.13M | 3.62M | 5.68M |
| Current deferred revenue | 0.23M | - | - | 0.82M | 1.11M |
| Net debt | -3.52115M | -6.58395M | -20.00282M | -18.12764M | -30.98656M |
| Short term debt | 0.27M | 0.29M | 0.29M | 0.31M | 0.37M |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 0.34M | 0.37M | 0.48M | 0.57M | 0.55M |
| Other stockholder equity | 329.91M | 327.85M | 272.28M | 286.89M | 286.38M |
| Property plant equipment | - | 0.40M | 0.54M | 0.63M | 0.57M |
| Total current assets | 4.23M | 7.83M | 21.94M | 19.49M | 32.39M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | 4.91M | 16.93M | 14.61M | 25.52M |
| Short term investments | 0.00085M | 0.00316M | 0.02M | 0.06M | 0.01M |
| Net receivables | 0.15M | 0.60M | 0.32M | 0.07M | 0.12M |
| Long term debt | - | - | - | - | - |
| Inventory | - | -871.60461M | - | - | - |
| Accounts payable | 0.98M | 1.28M | 1.79M | 0.98M | 2.22M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 29.81M | 25.77M | 24.44M | 8.58M | 7.15M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | 32.85M | 32.85M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 0.05M | 0.05M | 0.06M | 0.06M | 0.07M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 0.41M | 0.45M | 0.60M | 0.69M | 0.64M |
| Capital lease obligations | 0.34M | 0.37M | 0.48M | 0.57M | 0.55M |
| Long term debt total | - | - | - | - | 0.18M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | 0.00297M | 0.00124M | -0.05941M | -0.04325M | -0.04732M |
| Change to liabilities | -0.42739M | 0.06M | -2.04192M | 3.03M | 0.86M |
| Total cashflows from investing activities | 0.00297M | -0.03031M | -0.05941M | -0.04325M | -0.05637M |
| Net borrowings | -0.28808M | -0.30962M | -0.36741M | -0.31679M | -0.31679M |
| Total cash from financing activities | 3.10M | 16.40M | 0.05M | -0.46370M | 37.39M |
| Change to operating activities | 0.86M | -0.56921M | 0.17M | -0.52664M | -0.03718M |
| Net income | -20.80421M | -15.35191M | -12.85860M | -14.78060M | -1.64480M |
| Change in cash | -13.52775M | 1.79M | -12.84176M | -10.13335M | 39.09M |
| Begin period cash flow | 20.48M | 18.70M | 31.54M | 41.67M | 2.58M |
| End period cash flow | 6.96M | 20.48M | 18.70M | 31.54M | 41.67M |
| Total cash from operating activities | -16.43718M | -14.70519M | -12.18007M | -9.48210M | 1.75M |
| Issuance of capital stock | 1.68M | 13.96M | 0.72M | 0.00599M | 40.49M |
| Depreciation | 0.32M | 0.35M | 0.38M | 0.33M | 0.00294M |
| Other cashflows from investing activities | - | - | - | -0.01480M | -0.04732M |
| Dividends paid | 0.00000M | 0.00000M | 0.00000M | 0.00000M | 0.00000M |
| Change to inventory | - | - | - | - | - |
| Change to account receivables | -0.25209M | -0.09641M | 0.05M | 0.15M | -0.07713M |
| Sale purchase of stock | - | - | - | 0.00599M | 40.48M |
| Other cashflows from financing activities | 1.71M | 2.75M | -0.30620M | -0.15289M | -3.09772M |
| Change to netincome | 3.89M | 1.06M | 2.12M | 2.31M | 2.65M |
| Capital expenditures | 0.00058M | 0.03M | 0.06M | 0.03M | 0.00905M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | 0.16M | -0.76157M | -1.82154M | 2.66M | 0.74M |
| Stock based compensation | 3.68M | 1.18M | 1.18M | 1.69M | 2.30M |
| Other non cash items | 0.20M | 0.03M | 0.97M | 0.52M | 0.33M |
| Free cash flow | -16.43777M | -14.73673M | -12.23948M | -9.51056M | 1.74M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ADXN Addex Therapeutics Ltd |
0.27 3.32% | 8.38 | - | - | 9.68 | 0.69 | 7.47 | -0.757 |
| NVO Novo Nordisk A/S |
-2.25 2.82% | 77.58 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
-1.25 1.54% | 79.75 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-2.04 0.45% | 453.41 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
6.40 1.21% | 535.64 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The Charcot"Marie"Tooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.
Chemin des Mines, 9, Geneva, Switzerland, 1202
| Name | Title | Year Born |
|---|---|---|
| Mr. Timothy Mark Dyer | Co-Founder, CEO & Director | 1968 |
| Dr. Roger G. Mills M.D. | Chief Medical Officer & Director | 1957 |
| Mr. Lénaic Teyssédou | Head of Fin. | 1986 |
| Dr. Jean-Philippe Rocher Ph.D. | Head of Discovery - Chemistry | 1959 |
| Dr. Robert Lutjens | Head of Discovery - Biology | 1968 |
| Dr. Mikhail Kalinichev Ph.D. | Head of Translational Science | 1968 |
| Dr. Werner Henrichi Ph.D. | Consultant | 1943 |
| Mr. Lénaic Teyssédou | Head of Finance | 1986 |
| Dr. Mikhail Kalinichev Ph.D. | Head of Translational Science | 1967 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes. This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API. Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...